What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2011, Issue , 2011, Pages 205-207

  Scott, Emma ^a   Reece, Donna ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; DRUG DERIVATIVE; LENALIDOMIDE; PYRAZINE DERIVATIVE; THALIDOMIDE;

ARTICLE; AUTOTRANSPLANTATION; CASE REPORT; HUMAN; MAINTENANCE CHEMOTHERAPY; MALE; METHODOLOGY; MIDDLE AGED; MULTIPLE MYELOMA; PATHOLOGY; RISK FACTOR; SECOND CANCER; STEM CELL TRANSPLANTATION;

BORONIC ACIDS; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; PYRAZINES; RISK FACTORS; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84859399172     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2011.1.205     Document Type: Article

References (0)